Hematology News and Research RSS Feed - Hematology News and Research

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.
KAIST researchers develop bio-medical imaging tool to view, analyze live cells

KAIST researchers develop bio-medical imaging tool to view, analyze live cells

Professor YongKeun Park of the Physics Department at the Korea Advanced Institute of Science and Technology and his research team have developed a powerful method for 3D imaging of live cells without staining. The researchers announced the launch of their new microscopic tool, the holotomography (HT)-1, to the global marketplace through a Korean start-up that Professor Park co-founded, TomoCube. [More]
Simple tips to help parents and children lead a healthy life

Simple tips to help parents and children lead a healthy life

Obesity is almost at epidemic proportions; it has more than doubled in children and tripled in adolescents in the past 30 years nationwide. Rosa Cataldo, DO, MPH, Director of the Healthy Weight & Wellness Center at Stony Brook Children's Hospital, says that the most effective approach to addressing weight loss in children are lifestyle-based modifications that involve parents. [More]
Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Could playing better defense make bone marrow transplants more successful? With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense. [More]
Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease. [More]
Newly developed computer models can simulate stem cell transplant recovery

Newly developed computer models can simulate stem cell transplant recovery

Scientists at Virginia Commonwealth University have developed computer models that can simulate the recovery of the immune system in patients undergoing stem cell transplants. [More]
FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. [More]
Wake Forest Baptist offers DigniCap scalp cooling system to breast cancer patients undergoing chemotherapy

Wake Forest Baptist offers DigniCap scalp cooling system to breast cancer patients undergoing chemotherapy

Wake Forest Baptist Medical Center is the first medical center in the United States to offer the FDA-cleared DigniCap scalp cooling system to patients undergoing chemotherapy for breast cancer. [More]
Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania. [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
Twitter may be effective, untapped resource to boost patient enrollment in cancer clinical trials

Twitter may be effective, untapped resource to boost patient enrollment in cancer clinical trials

Twitter may be an effective, untapped resource to stimulate interest in cancer clinical trials and boost enrollment, physicians at the Abramson Cancer Center of the University of Pennsylvania suggest in a new research letter in JAMA Oncology. Analyzing thousands of lung cancer tweets on the social media site revealed that a surprisingly large number were about clinical trials, particularly ones on immunotherapy, although none were used for recruitment. [More]
High-fat diet may make intestinal stem cells to become cancerous

High-fat diet may make intestinal stem cells to become cancerous

Over the past decade, studies have found that obesity and eating a high-fat, high-calorie diet are significant risk factors for many types of cancer. Now, a new study from Whitehead Institute and MIT's Koch Institute for Integrative Cancer Research reveals how a high-fat diet makes the cells of the intestinal lining more likely to become cancerous. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
IMP's Johannes Zuber receives German Cancer Prize 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Johannes Zuber, group leader at the Research Institute of Molecular Pathology (IMP) in Vienna, receives the German Cancer Prize 2016 in the category of experimental cancer research. [More]
Ohio State researchers working on new way to treat drug-resistant cancer

Ohio State researchers working on new way to treat drug-resistant cancer

Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that the ancient Greeks would approve of--only it's not a Trojan horse, but DNA that hides the invading force. [More]
Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
New way to analyze MRI data may offer treatment guidance for breast cancer patients

New way to analyze MRI data may offer treatment guidance for breast cancer patients

For women with the most common type of breast cancer, a new way to analyze magnetic resonance images (MRI) data appears to reliably distinguish between patients who would need only hormonal treatment and those who also need chemotherapy, researchers from Case Western Reserve University report. [More]
CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

Children's Hospital Los Angeles and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay would be CHLA's first NGS panel designed to target biomarkers associated with childhood cancers. [More]
DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients. [More]
African Americans with common genetic variants at increased risk for blood clots

African Americans with common genetic variants at increased risk for blood clots

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), identifies common genetic variants predominantly found in African Americans that double their risk for blood clots. [More]
Advertisement
Advertisement